More research is warranted to determine the clinical significance of genomic profiling of CTCs during KRAS-mediated CRC carcinogenesis in predicting responsiveness to anti-CTLA-4 targeted therapy. The gene discussed is KRAS; the disease is colorectal carcinoma.